Arzt Michael, Floras John S, Logan Alexander G, Kimoff R John, Series Frederic, Morrison Debra, Ferguson Kathleen, Belenkie Israel, Pfeifer Michael, Fleetham John, Hanly Patrick, Smilovitch Mark, Ryan Clodagh, Tomlinson George, Bradley T Douglas
University of Toronto, Toronto, Ontario, Canada.
Circulation. 2007 Jun 26;115(25):3173-80. doi: 10.1161/CIRCULATIONAHA.106.683482. Epub 2007 Jun 11.
In the main analysis of the Canadian Continuous Positive Airway Pressure (CPAP) for Patients with Central Sleep Apnea (CSA) and Heart Failure Trial (CANPAP), CPAP had no effect on heart transplant-free survival; however, CPAP only reduced the mean apnea-hypopnea index to 19 events per hour of sleep, which remained above the trial inclusion threshold of 15. This stratified analysis of CANPAP tested the hypothesis that suppression of CSA below this threshold by CPAP would improve left ventricular ejection fraction and heart transplant-free survival.
Of the 258 heart failure patients with CSA in CANPAP, 110 of the 130 randomized to the control group and 100 of the 128 randomized to CPAP had sleep studies 3 months later. CPAP patients were divided post hoc into those whose apnea-hypopnea index was or was not reduced below 15 at this time (CPAP-CSA suppressed, n=57, and CPAP-CSA unsuppressed, n=43, respectively). Their changes in left ventricular ejection fraction and heart transplant-free survival were compared with those in the control group. Despite similar CPAP pressure and hours of use in the 2 groups, CPAP-CSA-suppressed subjects experienced a greater increase in left ventricular ejection fraction at 3 months (P=0.001) and significantly better transplant-free survival (hazard ratio [95% confidence interval] 0.371 [0.142 to 0.967], P=0.043) than control subjects, whereas the CPAP-CSA-unsuppressed group did not (for left ventricular ejection fraction, P=0.984, and for transplant-free survival, hazard ratio 1.463 [95% confidence interval 0.751 to 2.850], P=0.260).
These results suggest that in heart failure patients, CPAP might improve both left ventricular ejection fraction and heart transplant-free survival if CSA is suppressed soon after its initiation.
在加拿大针对中枢性睡眠呼吸暂停(CSA)合并心力衰竭患者的持续气道正压通气(CPAP)试验(CANPAP)的主要分析中,CPAP对无心脏移植生存率无影响;然而,CPAP仅将平均呼吸暂停低通气指数降至每小时睡眠19次事件,仍高于试验纳入阈值15。CANPAP的这项分层分析检验了以下假设:CPAP将CSA抑制至该阈值以下可改善左心室射血分数和无心脏移植生存率。
在CANPAP的258例CSA合并心力衰竭患者中,随机分配至对照组的130例中有110例以及随机分配至CPAP组的128例中有100例在3个月后进行了睡眠研究。CPAP组患者事后被分为此时呼吸暂停低通气指数降至15以下或未降至15以下的两组(分别为CPAP-CSA被抑制组,n = 57,和CPAP-CSA未被抑制组,n = 43)。将他们的左心室射血分数变化和无心脏移植生存率与对照组进行比较。尽管两组的CPAP压力和使用时间相似,但CPAP-CSA被抑制组在3个月时左心室射血分数的增加幅度更大(P = 0.001),且无移植生存率显著优于对照组(风险比[95%置信区间]0.371[0.142至0.967],P = 0.043),而CPAP-CSA未被抑制组则不然(左心室射血分数方面,P = 0.984;无移植生存率方面,风险比1.463[95%置信区间0.751至2.850],P = 0.260)。
这些结果表明,在心力衰竭患者中,如果CPAP启动后不久CSA即被抑制,CPAP可能会改善左心室射血分数和无心脏移植生存率。